PMC8723866_01
Onset lesion of the nasal infection.
CRIDM2021-3801949.001.jpg
PMC8723866_01_CRIDM2021-3801949.001.jpg
fig1
The disease started around May 2018 with a small localized lesion (Figure 1).
Erythematous appearance covering the entire lobe of the nose.
CRIDM2021-3801949.002.jpg
PMC8723866_01_CRIDM2021-3801949.002.jpg
fig2
Four months later, the lesion has spread over the entire lobe of the nose and appeared erythematous (Figure 2).
CT scan of the facial mass: no destruction of the nasal septum.
CRIDM2021-3801949.003.jpg
PMC8723866_01_CRIDM2021-3801949.003.jpg
fig3
As for the X-ray results, no lysis of the specific bones of the nose was detected and no damage to the underlying mucosa was observed (Figure 3).
Inflammatory nasal swelling due to Leishmania tropica.
CRIDM2021-3801949.004.jpg
PMC8723866_01_CRIDM2021-3801949.004.jpg
fig4
CL. Clinical examination revealed an ulcerative, infiltrated, and poorly limited erythematous placard (Figure 4).
PCR-RFLP technique used for identification of Leishmania species (enzymatic digestion of PCR fragments by Mn1-I).
CRIDM2021-3801949.005.jpg
PMC8723866_01_CRIDM2021-3801949.005.jpg
fig5
However, the results showed that the electrophoretic profile was comparable to that of L. tropica (Figure 5).
Response of the lesion to meglumine antimoniate treatment: one week after beginning of treatment.
CRIDM2021-3801949.006.jpg
PMC8723866_01_CRIDM2021-3801949.006.jpg
fig6
The initiation of treatment had shown good tolerance and satisfactory results (Figure 6).
Response of the lesion to meglumine antimoniate treatment: 2 weeks after beginning of treatment.
CRIDM2021-3801949.007.jpg
PMC8723866_01_CRIDM2021-3801949.007.jpg
fig7
A week later, a clear clinical improvement was noticed and the skin lesion healed completely without relapse (Figure 7).
Response of the lesion to meglumine antimoniate treatment: stopping treatment.
CRIDM2021-3801949.008.jpg
PMC8723866_01_CRIDM2021-3801949.008.jpg
fig8
Nevertheless, the patient still retains partial healing of the lesion (Figure 8).